Acquired by Novartis in August 2023 ($3.5B)o Member of Executive Committee and key other Chinook governance and alliances committees, including Development Review Committee, Chinese Joint Venture SanReno Joint Steering Committee, and Novartis/Chinook Transition Leadership.o Built fully outsourced CMC, manufacturing, supply chain teams and capabilities in a fully remote model.o Accountable for CMC, Clinical and Commercial Manufacturing, and Supply Chain for all portfolio small molecules and biologics programs from DC through launch and commercial.

Acquired by Eli Lilly and Co. in Feb. 2020o Strategic leader with prominent roles on key Dermira and Alliances committees (Eli Lilly and Co., Almirall, Maruho).o People leader with managerial responsibilities for up to 30 employees and a successful track record for fostering sustained high engagement and a culture of technical excellence with top-notch teams through partnerships, lay-offs, and acquisition. o Established Dermira’s fully virtual CMC, manufacturing, and supply chain capabilities from ground up to enable successful development, approval, and launch of QBREXZA® in 2018 as well as development of a portfolio of small molecules, biologics (lebrikizumab), and associated lifecycle management projects;Small Molecules development: Accountable for all CMC, drug substance, drug product development, lifecycle management, analytical and bioanalytical development for all Dermira small molecule programs from candidate selection to launch and commercial manufacturing, including QBREXZA launch supply chain and procurement responsibilities. Lebrikizumab development: Accountable for all CMC, devices, drug device combinations, mAb formulation characterization, components and vendor selection, contract manufacturing organizations and contract testing laboratories selection, technology transfers, process characterization, analytical development and analytical and bioanalytical method transfers, stability programs, process performance qualification preparedness, IND amendments, BLA preparedness, CTA, IMPD, alliance and partnership management (Roche/Genentech and Almirall).

Group mentoring initiative focused on addressing growth needs of middle management levels.

Founded in 2013 to serve as the stewards of the company culture and values.